A tariff proclamation signed by President Trump in the spring of 2026 does not treat every imported prescription drug the same way. Depending on where a brand-name medication or its active ingredient was made, an importer can face a duty rate anywhere from zero to 100 percent, and the gap between those numbers is now showing up in pharmaceutical supply chains as a second wave of the policy takes effect. For a retiree filling brand-name prescriptions through a Medicare Part D or Medicare Advantage plan, the country where a drug is manufactured, not just the drug itself, now has a direct bearing on cost.
The Two-Tier Timeline Behind the Headline Rate
Proclamation 11020, signed April 2, 2026, invokes Section 232 of the Trade Expansion Act to impose a 100 percent ad valorem duty on imports of patented pharmaceuticals and their active pharmaceutical ingredients, the category of drugs that are typically brand-name and still under patent rather than generic. The Commerce Department concluded that roughly 53 percent of patented pharmaceutical products sold domestically are made abroad, with only 15 percent of the active ingredients behind them produced inside the country, and framed that reliance as a national security concern rather than a routine trade dispute.
The 100 percent rate did not switch on for every importer at once. Under the proclamation’s own terms, it took effect at 12:01 a.m. Eastern on July 31, 2026, for the drugmakers named in Annex III to the proclamation, and reaches every other importer of patented pharmaceuticals and ingredients on September 29, 2026, a date now three weeks away. Those annexes, filed alongside the proclamation itself, spell out which specific products fall under the tariff and which companies were assigned the earlier start date.
Free retirement updates: Miss an enrollment or claim deadline and it may be gone. Our free Retirement Shield newsletter keeps readers ahead of the ones that matter. Get the free newsletter.
Why Europe, Japan, South Korea and Switzerland Pay 15 Percent
The same proclamation that set the 100 percent default rate also built in country-specific carve-outs tied to existing trade arrangements. Patented pharmaceuticals and ingredients from Japan, the European Union, South Korea, and Switzerland and Liechtenstein jointly are set at 15 percent rather than the full 100 percent, a rate the administration ties to pharmaceutical-related commitments already embedded in trade deals with those governments. The United Kingdom gets an even lower rate, 10 percent, reflecting what the proclamation describes as an agreement in principle reached with the U.S. as of December 1, 2025.
That UK rate is not necessarily permanent at 10 percent. The proclamation directs that it “shall reduce to zero” once a future U.S.-UK agreement on pharmaceutical pricing requires it, and specifies that the Commerce Secretary must publish a separate Federal Register notice if and when that happens. No such notice has been identified as of this writing, which means the 10 percent rate for British-made patented drugs is the current, operative figure rather than a placeholder awaiting confirmation.
The Exemption List That Protects Most Retirees’ Medicine Cabinets
The proclamation’s most consequential carve-out for older Americans may be the one that gets the least attention: generic drugs are not covered at all. The text states plainly that generic pharmaceuticals and their associated ingredients, “including biosimilar products,” are not subject to the Section 232 tariff at this time, a determination that also extends to purchases for the government’s Strategic API Reserve. Separately, the proclamation sets a zero tariff rate for orphan drugs approved for rare diseases, nuclear medicines, plasma-derived therapies, fertility treatments, cell and gene therapies, antibody-drug conjugates, and certain other specialty products the Commerce Secretary designates.
That distinction matters because most prescriptions filled by Medicare beneficiaries are generics rather than patented brand-name drugs, meaning the bulk of a typical retiree’s regular refills sit outside the tariff entirely. Where the tariff does reach a Medicare Part D or Medicare Advantage enrollee is on brand-name, still-patented medications, the drugs most likely to carry list prices that flow through a plan’s deductible, initial coverage, and cost-sharing tiers. A higher import cost on a patented drug does not automatically become a higher co-payment overnight, since formulary pricing, manufacturer rebates, and plan design all sit between an import duty and a pharmacy counter, but the tariff structure itself increases the cost pressure specifically on the branded medications that already carry the highest sticker prices. Those brand-name drugs are typically the ones placed on a plan’s higher formulary tiers, where an enrollee’s coinsurance is calculated as a percentage of the drug’s price rather than a flat dollar copay, so a manufacturer passing tariff costs through to list price would show up first for beneficiaries taking imported patented drugs for conditions such as autoimmune disease, certain cancers, or other specialty diagnoses, not for the blood-pressure or cholesterol generics that make up most retirees’ daily regimens.
What the September 29 Deadline Still Leaves Open
The distinction between the drugmakers already paying the tariff since July 31 and the broader industry facing the September 29 start date is not cosmetic. A Ropes & Gray attorney alert published shortly after the proclamation was signed flagged the two-tier timeline and the exemption categories as the details importers most needed to track heading into the second effective date, since companies without an onshoring agreement or an MFN pricing arrangement with the Department of Health and Human Services get no special treatment once their compliance grace period ends.
Nothing in the record reviewed for this article shows the proclamation has been amended, suspended, or narrowed since April. Section 232 tariffs rest on different legal authority than the earlier round of tariffs the Supreme Court curtailed in February 2026, and that ruling left this pharmaceutical proclamation untouched. Absent a new Federal Register notice changing a rate, the country-tier structure that took effect this summer, and the September 29 deadline now bearing down on the rest of the pharmaceutical import industry, both stand as published. For a Medicare Part D or Medicare Advantage enrollee trying to gauge personal exposure before that date, the proclamation itself points to the two facts that matter most: whether a specific prescription is a patented brand-name drug or its generic equivalent, and whether the country of manufacture is one of the four covered by the 15 percent rate, the UK’s 10 percent, or the full 100 percent charged everywhere else.
This article was produced with the assistance of AI and reviewed by The Financial Wire editorial team.
More Financial Reading
- Bank statements: how long to keep them and when to toss them
- How many CDs can you park at 1 bank? FDIC rules you must know
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
